Skip to main content
Top
Published in: Supportive Care in Cancer 11/2012

01-11-2012 | Original Article

Dying of hematologic patients—treatment characteristics in a German University Hospital

Authors: Patrick Brück, Malgorzata Pierzchlewska, Marta Kaluzna-Oleksy, Maria Elizabeth Ramos Lopez, Mathias Rummel, Dieter Hoelzer, Angelika Böhme

Published in: Supportive Care in Cancer | Issue 11/2012

Login to get access

Abstract

The treatment of hematologic patients in palliative situations remains a major challenge as there are special clinical needs, e.g., transfusions and the high risk for infectious complications with subsequent use of broad anti-infective treatment. Furthermore, most hematologic patients have a relatively long history of disease and are acquainted with “their” wards; that is why most are treated on these hematologic and not on specialized palliative wards. The standardized approach to the care of hematologic patients with curative treatment intention is probably not fully appropriate for palliative patients. In order to evaluate the current situation of treatment characteristics in a German university hospital, we retrospectively evaluated the medical documentation of all patients who died on a hematologic ward between 2005 and 2008. While we found a high number of chemotherapeutic, anti-infective, analgesic, and sedative treatments, of transfusions, of treatment on the intensive care units, and of invasive nature, non-somatic interventions were rather scarce. Symptom control, e.g., for bleeding events or pain, was frequently not adequately achieved. With regard to the palliative situation, a holistic approach with the maintenance of patients’ autonomy and the preference for dying at home, the treatment of hematologic patients in a palliative situation has to be reconsidered.
Literature
2.
go back to reference McGrath P, Holewa H (2007) Special considerations for haematology patients in relation to end-of-life care: Australian findings. Eur J Cancer Care 16:164–171CrossRef McGrath P, Holewa H (2007) Special considerations for haematology patients in relation to end-of-life care: Australian findings. Eur J Cancer Care 16:164–171CrossRef
3.
go back to reference Nightingale E (2000) Quality in palliative care. Aust Health Cons 3(2):39–40 Nightingale E (2000) Quality in palliative care. Aust Health Cons 3(2):39–40
4.
go back to reference Cella DF (1995) Measuring quality of life in palliative care. Semin Oncol 22(2 Suppl 3):73–81PubMed Cella DF (1995) Measuring quality of life in palliative care. Semin Oncol 22(2 Suppl 3):73–81PubMed
5.
go back to reference Strasser F, Blum D, Bueche D (2010) Invasive palliative interventions: when are they worth it and when are they not? Cancer J 16(5):483–487PubMedCrossRef Strasser F, Blum D, Bueche D (2010) Invasive palliative interventions: when are they worth it and when are they not? Cancer J 16(5):483–487PubMedCrossRef
6.
go back to reference Bookbinder M, McHugh ME (2010) Symptom management in palliative care and end of life care. Nurs Clin North Am 45(3):271–327PubMedCrossRef Bookbinder M, McHugh ME (2010) Symptom management in palliative care and end of life care. Nurs Clin North Am 45(3):271–327PubMedCrossRef
7.
go back to reference Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C, for the German Acute Myeloid Leukaemia Cooperative Group and the Study Alliance Leukemia Investigators (2010) Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 376:2000–2008 Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C, for the German Acute Myeloid Leukaemia Cooperative Group and the Study Alliance Leukemia Investigators (2010) Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 376:2000–2008
8.
go back to reference Niscola P, Tendas A, Scaramucci L, Giovaninni M, Cupelli L, De Sanctis V, Brunetti GA, Bondanini F, Palumbo R, Lamanda M, Battistini R, Cartoni C, Romani C, Arcuri E (2011) Pain in malignant hematology. Expert Rev Hematol 4(1):81–93PubMedCrossRef Niscola P, Tendas A, Scaramucci L, Giovaninni M, Cupelli L, De Sanctis V, Brunetti GA, Bondanini F, Palumbo R, Lamanda M, Battistini R, Cartoni C, Romani C, Arcuri E (2011) Pain in malignant hematology. Expert Rev Hematol 4(1):81–93PubMedCrossRef
9.
go back to reference Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Roca I, Casas J, Sawe J, Twycross RG, Ventafridda V (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Expert Working Group of the Research Network of the European Association for Palliative Care. Br J Cancer 84(5):587–593PubMedCrossRef Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Roca I, Casas J, Sawe J, Twycross RG, Ventafridda V (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Expert Working Group of the Research Network of the European Association for Palliative Care. Br J Cancer 84(5):587–593PubMedCrossRef
10.
go back to reference Muller-Busch HC, Andres I, Jehser T (2003) Sedation in palliative care—a critical analysis of 7 years experience. BMC Palliat Care 2(1):2PubMedCrossRef Muller-Busch HC, Andres I, Jehser T (2003) Sedation in palliative care—a critical analysis of 7 years experience. BMC Palliat Care 2(1):2PubMedCrossRef
11.
go back to reference Sykes N, Thorns A (2003) Sedative use in the last week of life and the implications for end-of-life decision making. Arch Intern Med 163:341–344PubMedCrossRef Sykes N, Thorns A (2003) Sedative use in the last week of life and the implications for end-of-life decision making. Arch Intern Med 163:341–344PubMedCrossRef
12.
go back to reference Bauduer F, Capdupuy C, Renoux M (2000) Characteristics of deaths in a department of oncohaematology within a general hospital: a study of 81 cases. Supp Care Cancer 8:302–306CrossRef Bauduer F, Capdupuy C, Renoux M (2000) Characteristics of deaths in a department of oncohaematology within a general hospital: a study of 81 cases. Supp Care Cancer 8:302–306CrossRef
13.
go back to reference Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ (2008) Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 26:3860–3866PubMedCrossRef Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ (2008) Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 26:3860–3866PubMedCrossRef
14.
go back to reference Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS (2003) Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 138:639–643PubMed Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS (2003) Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 138:639–643PubMed
15.
go back to reference Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22(2):315–321PubMedCrossRef Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22(2):315–321PubMedCrossRef
16.
go back to reference Martoni AA, Tanneberger S, Mutri V (2007) Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use. Tumori 93(5):417–422PubMed Martoni AA, Tanneberger S, Mutri V (2007) Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use. Tumori 93(5):417–422PubMed
17.
go back to reference Koedoot CG, Oort FJ, de Haan RJ, Bakker PJ, de Graeff A, de Haes JC (2004) The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are: palliative chemotherapy and watchful-waiting. Eur J Cancer 40(2):225–235PubMedCrossRef Koedoot CG, Oort FJ, de Haan RJ, Bakker PJ, de Graeff A, de Haes JC (2004) The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are: palliative chemotherapy and watchful-waiting. Eur J Cancer 40(2):225–235PubMedCrossRef
18.
go back to reference Sullivan AM, Lakoma MD, Matsuyama RK, Rosenblatt L, Arnold RM, Block SD (2007) Diagnosing and discussing imminent death in the hospital: a secondary analysis of physician interviews. J Palliat Med 10(4):882–893PubMedCrossRef Sullivan AM, Lakoma MD, Matsuyama RK, Rosenblatt L, Arnold RM, Block SD (2007) Diagnosing and discussing imminent death in the hospital: a secondary analysis of physician interviews. J Palliat Med 10(4):882–893PubMedCrossRef
19.
go back to reference Mackillop WJ, Stewart WE, Ginsburg AD, Stewart SS (1998) Cancer patients’ perceptions of their disease and its treatment. Br J Cancer 58(3):355–358CrossRef Mackillop WJ, Stewart WE, Ginsburg AD, Stewart SS (1998) Cancer patients’ perceptions of their disease and its treatment. Br J Cancer 58(3):355–358CrossRef
20.
go back to reference Chow E, Andersson L, Wong R, Vachon M, Hruby G, Franssen E, Fung KW, Harth T, Pach B, Pope J, Connolly R, Schueller T, Stefaniuk K, Szumacher E, Hayter C, Finkelstein J, Danjoux C (2001) Patients with advanced cancer: a survey of the understanding of their illness and expectations from palliative radiotherapy for symptomatic metastases. Clin Oncol (R Coll Radiol) 13(3):204–208 Chow E, Andersson L, Wong R, Vachon M, Hruby G, Franssen E, Fung KW, Harth T, Pach B, Pope J, Connolly R, Schueller T, Stefaniuk K, Szumacher E, Hayter C, Finkelstein J, Danjoux C (2001) Patients with advanced cancer: a survey of the understanding of their illness and expectations from palliative radiotherapy for symptomatic metastases. Clin Oncol (R Coll Radiol) 13(3):204–208
21.
go back to reference Mack JW, Weeks JC, Wright AA, Block SD, Prigerson HG (2010) End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes for receipt of care consistent with preferences. J Clin Oncol 28(7):1203–1208PubMedCrossRef Mack JW, Weeks JC, Wright AA, Block SD, Prigerson HG (2010) End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes for receipt of care consistent with preferences. J Clin Oncol 28(7):1203–1208PubMedCrossRef
22.
go back to reference Hill QA (2010) Intensify, resuscitate or palliate: decision making in the critically ill patient with haematological malignancy. Blood Rev 24(1):17–25PubMedCrossRef Hill QA (2010) Intensify, resuscitate or palliate: decision making in the critically ill patient with haematological malignancy. Blood Rev 24(1):17–25PubMedCrossRef
23.
go back to reference Nosari A, Barberis M, Landonio G, Magnani P, Majno M, Oreste P, Sozzi P (1991) Infections in haematologic neoplasms: autopsy findings. Haematologica 76:135–140PubMed Nosari A, Barberis M, Landonio G, Magnani P, Majno M, Oreste P, Sozzi P (1991) Infections in haematologic neoplasms: autopsy findings. Haematologica 76:135–140PubMed
24.
go back to reference Oneschuk D, Fainsinger R, Demoissac D (2002) Antibiotic use in the last week of life in three different palliative care settings. J Palliat Care 18(1):25–28PubMed Oneschuk D, Fainsinger R, Demoissac D (2002) Antibiotic use in the last week of life in three different palliative care settings. J Palliat Care 18(1):25–28PubMed
25.
go back to reference Reinbolt RE, Shenk AM, White PH, Navari RM (2005) Symptomatic treatment of infections in patients with advanced cancer receiving hospice care. J Pain Symptom Manag 30:175–182CrossRef Reinbolt RE, Shenk AM, White PH, Navari RM (2005) Symptomatic treatment of infections in patients with advanced cancer receiving hospice care. J Pain Symptom Manag 30:175–182CrossRef
26.
go back to reference White PH, Kuhlenschmidt HL, Vancura BG, Navari RM (2003) Antimicrobial use in patients with advanced cancer receiving hospice care. J Pain Symptom Manag 25(5):438–443CrossRef White PH, Kuhlenschmidt HL, Vancura BG, Navari RM (2003) Antimicrobial use in patients with advanced cancer receiving hospice care. J Pain Symptom Manag 25(5):438–443CrossRef
27.
go back to reference Dunn A, Carter J, Carter H (2003) Anemia at the end of life: prevalence, significance, and causes in patients receiving palliative care. J Pain Symptom Manag 26:1132–1139CrossRef Dunn A, Carter J, Carter H (2003) Anemia at the end of life: prevalence, significance, and causes in patients receiving palliative care. J Pain Symptom Manag 26:1132–1139CrossRef
28.
go back to reference Stalfelt AM, Brodin H, Pettersson S, Eklöf A (2003) The final phase in acute myeloid leukaemia (AML): a study on bleeding, infection and pain. Leuk Res 27:481–488PubMedCrossRef Stalfelt AM, Brodin H, Pettersson S, Eklöf A (2003) The final phase in acute myeloid leukaemia (AML): a study on bleeding, infection and pain. Leuk Res 27:481–488PubMedCrossRef
29.
go back to reference Wandt H, Ehninger G, Gallmeier WM (2001) New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist 6:446–450PubMedCrossRef Wandt H, Ehninger G, Gallmeier WM (2001) New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist 6:446–450PubMedCrossRef
30.
go back to reference Bruera E, Belzile M, Watanabe S, Fainsinger RL (1996) Volume of hydration in terminal cancer patients. Supp Care Cancer 4:147–150CrossRef Bruera E, Belzile M, Watanabe S, Fainsinger RL (1996) Volume of hydration in terminal cancer patients. Supp Care Cancer 4:147–150CrossRef
31.
go back to reference Oh DY, Kim JH, Lee SH, Kim DW, Im SA, Kim TZ, Heo DS, Bang YJ, Kim NK (2007) Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. Supp Care Cancer 15:631–636CrossRef Oh DY, Kim JH, Lee SH, Kim DW, Im SA, Kim TZ, Heo DS, Bang YJ, Kim NK (2007) Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. Supp Care Cancer 15:631–636CrossRef
32.
go back to reference Higginson IJ, Sen-Gupta GJ (2000) Place of care in advanced cancer: a qualitative systematic literature review of patient preferences. J Palliat Med 3(3):287–300PubMedCrossRef Higginson IJ, Sen-Gupta GJ (2000) Place of care in advanced cancer: a qualitative systematic literature review of patient preferences. J Palliat Med 3(3):287–300PubMedCrossRef
33.
go back to reference Niscola P, de Fabritiis P, Cartoni C, Romani C, Sorrentino F, Dentamaro T, Piccioni D, Scaramucci L, Giovannini M, Amadori S, Mandelli F (2006) Home care management of patients affected by hematologic malignancies: a review. Haematologica 91(11):1523–1529PubMed Niscola P, de Fabritiis P, Cartoni C, Romani C, Sorrentino F, Dentamaro T, Piccioni D, Scaramucci L, Giovannini M, Amadori S, Mandelli F (2006) Home care management of patients affected by hematologic malignancies: a review. Haematologica 91(11):1523–1529PubMed
Metadata
Title
Dying of hematologic patients—treatment characteristics in a German University Hospital
Authors
Patrick Brück
Malgorzata Pierzchlewska
Marta Kaluzna-Oleksy
Maria Elizabeth Ramos Lopez
Mathias Rummel
Dieter Hoelzer
Angelika Böhme
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 11/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1417-8

Other articles of this Issue 11/2012

Supportive Care in Cancer 11/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine